Immunoforge

ImmunoForge is a clinical-stage, venture-backed biopharmaceutical company based in Seoul, South Korea, specializing in the development of innovative therapies for muscular, rare, and metabolic diseases. The company utilizes two proprietary technology platforms: the ELP (Elastin-Like Polypeptide) platform, which uses recombinant biopolymers to extend the circulating half-life of proteins and peptides, and the LMT15 platform, a next-generation blood-brain barrier (BBB) shuttle technology designed to improve CNS drug delivery. By fusing these platforms, the company creates modalities that provide both efficient BBB penetration and long-acting administration, enabling more convenient dosing schedules such as weekly or monthly injections.

These platforms are central to ImmunoForge's mission to address critical therapeutic gaps, with a pipeline that includes clinical-stage assets like PF1801, currently in Phase 2 trials for polymyositis and dermatomyositis, and PF1804, targeted for Duchenne muscular dystrophy-associated cardiomyopathy. Through strategic global partnerships and research collaborations, including recognition from entities such as Novo Nordisk, the company aims to apply its technology to a broad range of CNS and metabolic disease candidates. ImmunoForge's work is driven by a focus on enhancing drug efficacy, safety, and patient convenience through its advanced pharmacological delivery solutions.